NewAmsterdam Pharma Co N.V.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

NAMS$19.18+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For the three months ended September 30,		For the nine months ended September 30,
	2025	2024	2025	2024
(In thousands of USD, except per share amounts)
Revenue	348	29,111	22,471	32,791
Operating expenses:
Research and development expenses	30,971	35,702	103,238	116,511
Selling, general and administrative expenses	24,520	18,412	78,936	49,340
Total operating expenses	55,491	54,114	182,174	165,851
Operating loss	(55,143)	(25,003)	(159,703)	(133,060)
Other income (expense):
Interest income	6,713	4,443	21,119	12,396
Fair value change – earnout	—	(5,414)	3,992	(11,020)
Fair value change – warrants	(23,792)	4,644	(7,440)	(19,008)
Loss on disposal of property, plant and equipment	(1)	—	(1)	—
Foreign exchange gains/(losses)	218	4,682	13,137	1,270
Loss before tax	(72,005)	(16,648)	(128,896)	(149,422)
Income tax expense (benefit)	—	(1)	—	(1)
Loss for the period	(72,005)	(16,647)	(128,896)	(149,421)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax	313	—	173	—
Total comprehensive loss for the period, net of tax	(71,692)	(16,647)	(128,723)	(149,421)
Net loss per ordinary share
Basic and diluted	$(0.61)	$(0.18)	$(1.09)	$(1.61)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.